Andrea Spallanzani

Modena, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Liver Transplantation Following Hepatocellular Carcinoma Rupture and Long-Term Immunotherapy: A Case Report.

Liver Transplantation Following Hepatocellular Carcinoma Rupture and Long-Term Immunotherapy: A Case Report.

Journal: Journal of gastrointestinal cancer

Published: April 11, 2026

Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?

Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?

Journal: Expert opinion on biological therapy

Published: March 05, 2026

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center.

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center.

Journal: Frontiers in digital health

Published: December 04, 2025

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

Journal: ESMO open

Published: October 03, 2025

Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.

Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 08, 2025

Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.

Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.

Journal: ESMO open

Published: April 12, 2025

Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study).

Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study).

Journal: Cancer gene therapy

Published: April 03, 2025

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial.

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial.

Journal: BMC cancer

Published: September 23, 2024

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 28, 2024

Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.

Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic.

Journal: The oncologist

Published: June 26, 2024

Spontaneous Regression of an Inflammatory Myofibroblastic Tumor: A Case Report and a Review of the Literature.

Spontaneous Regression of an Inflammatory Myofibroblastic Tumor: A Case Report and a Review of the Literature.

Journal: Case reports in oncology

Published: May 28, 2024

Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation.

Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation.

Journal: Critical reviews in oncology/hematology

Published: May 23, 2024

Showing 1-12 of 85

Last Updated: 09/26/2026